An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome-Reference-Cited by-同舟云学术

An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome

Published:2016-12-22 Issue:3 Volume:161 Page:567-574
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

de Vries Schultink A. H. M.,Alexi X.,van Werkhoven E.,Madlensky L.,Natarajan L.,Flatt S. W.,Zwart W.,Linn S. C.,Parker B. A.,Wu A. H. B.,Pierce J. P.,Huitema A. D. R.,Beijnen J. H.

Funder

A Sister's Hope

National Cancer Institute

Genentech

GlaxoSmithKline

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-4083-6.pdf

Reference33 articles.

1. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials. Lancet 365:1687–1717

2. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805–816

3. Gray R, Rea D, Handley K (2013) ATTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31: suppl; abstr 5

4. Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12:1101–1108

5. Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Solanidine Metabolites as Diet‐Derived Biomarkers of CYP2D6‐Mediated Tamoxifen Metabolism in Breast Cancer Patients;Clinical Pharmacology & Therapeutics;2024-07-22

2. Antitumor Activity of Antiestrogen-Cytostatics and Their Binding Affinity with Estrogen Receptors;Pharmaceutical Chemistry Journal;2024-01

3. A preliminary study on the association of tamoxifen, endoxifen, and 4-hydroxytamoxifen with blood lipids in patients with breast cancer;Biomedicine & Pharmacotherapy;2021-10

4. Effect of Genetic Variability in 20 Pharmacogenes on Concentrations of Tamoxifen and Its Metabolites;Journal of Personalized Medicine;2021-06-04

5. Analysis of tamoxifen and its metabolites in dried blood spot and volumetric absorptive microsampling: comparison and clinical application;Heliyon;2021-06